Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Who gives a ****e who lost what how can you lose big on a share worth 2p you deluded ppl think ppl buy 5 million shares come on here and bash or ramp knowing not thinking it will affect sp (oh he must be short his loosing millions) is that the best you can say
Actually You're right. I sold last year at a heavy loss but bought back in at 21p earlier this year. I really don't care what you think-I have no axe to grind either way. I just look at some of the comments and understand why most pi's lose money including me! Paranoia rules OK! BB
BB ? whats with your last post and the one you posted back in Dec? ButterflyBill
Posted in: FUM
RE: Here is what I said 03 Dec 2020 10:47 I'm with you Ody-Sold my 100k 2 months ago at a heavy loss after 5 years holding. Cash call soon will drop the price to 5-7p then i'll go back in-watch it climb to 15p or so and sell!
Hi-I have been a substantial (100,000) for over 5 years and am sitting on a small loss-got in at about 55p. I just wanted to comment on my perspective on Liambooth. I find his posts mainly factual and backed by websites he supplies and actually quite useful to calm down some of the ridiculous euphoria. If you trade on aim companies you have to be prepared to lose ALL your money if things don't turn out well. There have been many failures on this stock then why am I still in? There's still hope thats why! Good luck to all and lets try to calm the insults! BB
Maybe some people need to read what is defined as a Medical device and what defines a drug. Also how its easier to get some Medical devices approved especially in Europe. The irony is CSD500 had to undergo more rigorous scrutiny then MED3000 as it was a Medical device with an ancillary drug.
FDA approval always requires a full clinical trial or trials, whereas the CE Mark can be obtained through a clinical evaluation—a review of published data for existing equivalent devices. For a clinical evaluation, the only requirement is that the manufacturer conduct a postmarket clinical follow-up study once the CE Mark is obtained. However, this type of study is much easier to get approval for and therefore much less expensive to conduct than a clinical trial
Devices are by-and-large mechanical in nature and have an inert effect on the human body. Pharmaceuticals are chemical in nature and are designed to actively interact with the body’s metabolic or immune system.
He has clearly lost his savings and has zero credibility poor chap,literally.
MED3000 - Novel topical treatment for erectile dysfunction
Lead product, MED3000 is a unique and highly differentiated easy to use topical gel for erectile dysfunction which has Phase 3 clinical data demonstrating highly statistically significant improvement across all ED patient severities with potential peak sales of $1 billion.
External market assessments based on Market Research from Cello Health Consulting as a prescription product and Ipsos Group as an over the counter product, forecast that MED3000 could achieve combined peak annual sales in excess of US$1 billion1.
Ananda, clearly you are new here, those who have been here longer have put up with nearly 400 negative comments from booth, there has been much speculation why he is doing it, but clearly he is dishonest and has some dark purpose. I also think there may well be some psychological issue at play. I say it's good to keep bashing him although others think he should just be filtered and ignored.
Its in black and white in the 2017 links “ The respondents were shown a concept about MED2002”
“the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs”
In the Cello research the doctors were told it contained GTN as the vasodilator and it would be a prescription drug. They were not told it would not contain any active pharmacological drug and would have failed phase 3 drug trails and would only be a approved as a Medical device that worked only via manual massage and evaporative cooling stimulation.
As I said it is some doctor’s view that MED3000 is no longer highly differentiated from just rubbing in a menthol gel sexual lubricant which will also have evaporative cooling effects. All the respondents believed it worked via GTN the vasodilator as was the case back in 2017 with MED2002
The $1bn sales potential comes with a lot of fine print and based on a lot of assumptions. The Cello and IPSOS market research was released back in 2017 and is based on very out of date PDE5 pricing and when MED2002 was a potential drug. Not just a Medical device with no pharmacological action and developed out of the failed MED2005 Phase 3 drug trials. The market research was all based on asking a few respondents questions based on a concept of MED2002 ie a topical gel that had a GTN vasodilator mode of action. Or in IPSOS the idea of being able to rub a viagra type gel on.
“Previous market research conducted by Cello Health Consulting as a prescription product and Ipsos Group as an over the counter product on MED2005 showed potential peak sales in excess of $1bn. Whilst MED3000 is a slightly different proposition as it has a different mode of action, it offers the same benefits and therefore the Group believes that the market potential is similar. Manufacturers' Selling Prices 2018: Data available for 75 countries IQVIA IMS Health”